**Question:** Basiliximab is a monoclonal antibody against which of the following?

**Core Concept:** Monoclonal antibodies are laboratory-produced proteins that can mimic the immune system's ability to recognize and bind to specific molecules, thereby targeting specific cells, tissues, or molecules for diagnostic or therapeutic purposes.

**Why the Correct Answer is Right:** Basiliximab is a monoclonal antibody targeting the human interleukin-2 receptor (IL-2R) on activated T cells. By binding to IL-2R, basiliximab inhibits IL-2 signaling, which is essential for T cell survival, proliferation, and activation. This results in suppression of the immune response.

**Why Each Wrong Option is Incorrect:**

A. **Option A:** Interleukin-2 itself (IL-2) is a cytokine involved in immune response regulation. However, basiliximab does not target IL-2 directly but rather the receptor (IL-2R) on T cells.

B. **Option B:** This option is incorrect because basiliximab does not target the IL-2R on natural killer (NK) cells, which are another type of immune cell involved in immune response regulation. Basiliximab specifically targets T cells.

C. **Option C:** This option is incorrect because basiliximab does not target the major histocompatibility complex (MHC) molecules on antigen-presenting cells involved in antigen presentation and immune response activation. Basiliximab targets T cells through IL-2R inhibition.

D. **Option D:** Basiliximab does not target the CD4 receptor on helper T cells, which is involved in immune response regulation. Basiliximab targets T cells through IL-2R inhibition.

**Clinical Pearl:** Basiliximab is a key component of antidrug antibodies, which are used in immunosuppressive therapy for organ transplant recipients to prevent organ rejection and as an adjunctive therapy for severe autoimmune diseases like Crohn's disease and rheumatoid arthritis.

**Correct Answer:** D. CD4 receptor on helper T cells

**Why Each Wrong Option is Incorrect:**

A. **Option A:** Although IL-2 plays a role in immune response regulation, basiliximab does not target IL-2 directly. Instead, it inhibits the IL-2 receptor (IL-2R) on T cells.

B. **Option B:** Basiliximab targets T cells through inhibition of the IL-2 receptor (IL-2R), not the major histocompatibility complex (MHC) molecules, which are involved in antigen presentation and immune response activation.

C. **Option C:** Basiliximab does not target the CD8 receptor on cytotoxic T cells. Its primary action is on the CD4 receptor on helper T cells, inhibiting the immune response.

**Core Concept:** Immunosuppressive medications, like basiliximab, are essential in preventing organ transplant rejection and treating autoimmune disorders. They work by inhibiting T cell activation and proliferation, thereby reducing immune response and preventing organ damage.

In summary, basilixim